DelveInsight’s, “Checkpoint Inhibitors Competitive Landscape 2023” report provides comprehensive insights about 180+ Checkpoint Inhibitors Companies and 250+ drugs in the Checkpoint inhibitors Competitive landscape. It covers the Checkpoint Inhibitors therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Checkpoint Inhibitors Competitive Landscape Report

• DelveInsight’s Checkpoint Inhibitors report depicts a robust space with 180+ Glioma companies working to develop 250+ pipeline therapies for Checkpoint Inhibitors treatment.
• The leading Checkpoint Inhibitors Companies working in the market include BeBetter Med, BIOCAD, CanBas Co., Ltd., Laekna Therapeutics, Genentech, Alphamab Oncology, Hangzhou Sumgen Biotech, Harbour BioMed, Aurigene Discovery Technologies, BeiGene, Apollomics, BCN Biosciences, Phio Pharmaceuticals, Atridia, Jiangsu HengRui Medicine, EMD Serono, Innovent Biologics, Agenus, Eucure Biopharma, and others.
• Promising Checkpoint Inhibitors therapies in the various stages of development include M1774, M4076, Avelumab, S-531011, Pembrolizumab, Regorafenib (Stivarga, BAY73-4506), ASP8374, Magrolimab, TLPLDC Vaccine, and others.
• December 2023: Incyte Corporation announced a study of phase 2 clinical trials for INCB099280. This study is being conducted to determine the safety, tolerability, and preliminary efficacy of INCB099280 in participants with advanced solid tumors.
• December 2023: Candel Therapeutics Inc. announced a study of Phase 2 clinical trials for Aglatimagene besadenovec. The purpose of this clinical trial is to evaluate the effects of adding CAN-2409 + prodrug for stage III/IV NSCLC patients who are on standard of care first line immune checkpoint inhibitor (ICI) treatment with evidence that the clinical response is inadequate. CAN-2409 is a viral immunotherapy approach that induces tumor-infiltrating T-cells and a consequent PD-L1 up-regulation.
• December 2023: Hoffmann-La Roche announced a study of Phase 2 clinical trials for Tobemstomig, Tiragolumab, Pembrolizumab and Axitinib. This study will evaluate the efficacy, safety, and pharmacokinetics of tobemstomig (also known as RO7247669) in combination with axitinib alone or with tiragolumab (anti-TIGIT) and axitinib, as compared to pembrolizumab and axitinib in participants with previously untreated, unresectable locally advanced or metastatic clear-cell renal cell carcinoma (ccRCC).

 

Request a sample and discover the recent advances in Checkpoint Inhibitors Drugs @ Checkpoint Inhibitors Competitive Landscape Report

 

The Checkpoint Inhibitors report provides an in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition – deals values trends. The sub-segmentation is described in the Checkpoint Inhibitors report which provides company-company collaboration (licensing/partnering), company academic collaboration, and acquisition analysis in tabulated form.

 

Checkpoint Inhibitors Overview

Checkpoint inhibitors are a type of immunotherapy. They block proteins that stop the immune system from attacking the cancer cells. Cancer drugs do not always fit easily into a certain type of treatment. This is because some drugs work in more than one way and belong to more than one group. Checkpoint inhibitors are also described as a type of monoclonal antibody or targeted treatment.

 

Find out more about Checkpoint Inhibitors Analytical Perspective: In-depth Commercial Assessment @ Checkpoint Inhibitors Collaboration Analysis by Companies

 

Checkpoint Inhibitors Companies and Therapies

• BIOCAD: BCD-100
• CanBas Co., Ltd.: CBP501
• BeBetter Med: BEBT-260
• Laekna Therapeutics: FAZ053

 

Checkpoint Inhibitors Competitive Landscape

The Checkpoint Inhibitors report comprises of comparative assessment of Companies (by therapy, development stage, and technology).

 

Checkpoint Inhibitors Report Assessment

• Company Analysis
• Checkpoint Inhibitors Therapeutic Assessment
• Checkpoint Inhibitors Pipeline Assessment
• Inactive Checkpoint Inhibitors drugs assessment
• Checkpoint Inhibitors Unmet Needs

 

Learn more about the emerging Checkpoint Inhibitors Competitive Landscape @ Checkpoint Inhibitors Market Drivers and Barriers, Unmet Needs

 

Scope of the Checkpoint Inhibitors Competitive Landscape Report

• Coverage- Global
• Checkpoint Inhibitors Companies- BeBetter Med, BIOCAD, CanBas Co., Ltd., Laekna Therapeutics, Genentech, Alphamab Oncology, Hangzhou Sumgen Biotech, Harbour BioMed, Aurigene Discovery Technologies, BeiGene, Apollomics, BCN Biosciences, Phio Pharmaceuticals, Atridia, Jiangsu HengRui Medicine, EMD Serono, Innovent Biologics, Agenus, Eucure Biopharma, and others.
• Checkpoint Inhibitors therapies- M1774, M4076, Avelumab, S-531011, Pembrolizumab, Regorafenib (Stivarga, BAY73-4506), ASP8374, Magrolimab, TLPLDC Vaccine, and others.
• Checkpoint Inhibitors Therapeutics Assessment- Product Type, Stage and Product Type, Route of Administration, Stage and Route of Administration, Molecule Type, Stage and Molecule Type

 

Dive deep into rich insights for new drugs for Checkpoint Inhibitors Product Developmental Activities, Visit @ Checkpoint Inhibitors Research and Development Activities

 

Table of Content

1. Introduction
2. Executive Summary
3. Checkpoint inhibitors: Overview
4. Approved Therapies
5. Checkpoint inhibitors -Analytical Perspective: In-depth Commercial Assessment
6. Checkpoint Inhibitors Competitive Landscape
7. Checkpoint Inhibitors Therapeutic Assessment
8. Checkpoint inhibitors: Company and Product Profiles (Marketed Therapies)
9. Merck
10. Pembrolizumab
11. Checkpoint inhibitors: Company and Product Profiles (Pipeline Therapies)
12. Late Stage Products (Phase III)
13. BIOCAD
14. BCD-100
15. Drug profiles in the detailed report…..
16. Mid Stage Products (Phase II)
17. CanBas Co., Ltd.
18. CBP501
19. Drug profiles in the detailed report…..
20. Early Stage Products (Phase I)
21. BeBetter Med
22. BEBT-260
23. Drug profiles in the detailed report…..
24. Preclinical and Discovery Stage Products
25. Company Name
26. Product Name
27. Drug profiles in the detailed report…..
28. Inactive Products
29. Checkpoint inhibitors Unmet needs
30. Checkpoint inhibitors Market drivers and barriers
31. Appendix

 

For further information on the Checkpoint Inhibitors Report @ Checkpoint Inhibitors Preclinical and Discovery Stage Products

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/metastatic-melanoma-market